Agios Pharmaceuticals, Inc.
AGIONASDAQHealthcare● Active
$27.93
$-0.36(-1.27%)
Market Cap$1.7B
P/E Ratio—
52W High$46
52W Low$22.24
Agios Pharmaceuticals, Inc. (AGIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AGIO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$1.69
Est. -$1.81 · +6.6%
Revenue
$0.02B
Est. $0.01B · +56.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
AGIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$1.65 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | -$1.81 | -$1.69 | +6.6% | $0.02B | $0.01B | +56.0% |
| ▲ Q1 FY2026 | Feb 12, 2026 | -$1.97 | -$1.85 | +6.1% | $0.02B | $0.01B | +65.1% |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$1.93 | -$1.78 | +7.8% | $0.01B | $0.01B | +10.1% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$1.74 | -$1.93 | -10.9% | $0.01B | $0.01B | +21.2% |
| ▲ Q2 FY2025 | May 1, 2025 | -$1.80 | -$1.55 | +13.9% | $0.01B | $0.01B | -12.6% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$1.69 | -$1.74 | -3.0% | $0.01B | $0.01B | +14.8% |
| ▼ Q4 FY2024 | Oct 31, 2024 | $16.69 | $4.20 | -74.8% | $0.01B | $0.01B | -3.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$1.65
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
-$1.69
EPS Est.
-$1.81
EPS Surpr.
+6.6%
Revenue
$0.02B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
-$1.85
EPS Est.
-$1.97
EPS Surpr.
+6.1%
Revenue
$0.02B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$1.78
EPS Est.
-$1.93
EPS Surpr.
+7.8%
Revenue
$0.01B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$1.93
EPS Est.
-$1.74
EPS Surpr.
-10.9%
Revenue
$0.01B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$1.55
EPS Est.
-$1.80
EPS Surpr.
+13.9%
Revenue
$0.01B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$1.74
EPS Est.
-$1.69
EPS Surpr.
-3.0%
Revenue
$0.01B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
$4.20
EPS Est.
$16.69
EPS Surpr.
-74.8%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-1.98 | $-1.50 | $-1.02 | 3 |
| Q4 FY2026 | $-1.80 | $-1.36 | $-0.92 | 3 |
| Q3 FY2026 | $-1.73 | $-1.47 | $-1.31 | 7 |
| Q2 FY2026 | $-1.91 | $-1.65 | $-1.47 | 7 |
| Q1 FY2026 | $-1.82 | $-1.80 | $-1.78 | 6 |
| Q4 FY2025 | $-2.10 | $-1.95 | $-1.80 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.1B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +6.6% | $24.80 | $28.05 | +13.10% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +6.1% | $27.71 | $28.07 | +1.30% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +7.8% | $41.96 | $43.18 | +2.91% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -10.9% | $37.54 | $37.22 | -0.85% |
| ▲ Q2 FY2025 | May 1, 2025 | +13.9% | $29.69 | $30.94 | +4.21% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -3.0% | $32.81 | $33.30 | +1.49% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -74.8% | $46.30 | $44.43 | -4.04% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -7.0% | $46.40 | $44.50 | -4.09% |
Q2 FY2026+13.10%
Report Date
Apr 29, 2026
EPS Beat/Miss
+6.6%
Price Before
$24.80
Price After
$28.05
Q1 FY2026+1.30%
Report Date
Feb 12, 2026
EPS Beat/Miss
+6.1%
Price Before
$27.71
Price After
$28.07
Q4 FY2025+2.91%
Report Date
Oct 30, 2025
EPS Beat/Miss
+7.8%
Price Before
$41.96
Price After
$43.18
Q3 FY2025-0.85%
Report Date
Jul 31, 2025
EPS Beat/Miss
-10.9%
Price Before
$37.54
Price After
$37.22
Q2 FY2025+4.21%
Report Date
May 1, 2025
EPS Beat/Miss
+13.9%
Price Before
$29.69
Price After
$30.94
Q1 FY2025+1.49%
Report Date
Feb 13, 2025
EPS Beat/Miss
-3.0%
Price Before
$32.81
Price After
$33.30
Q4 FY2024-4.04%
Report Date
Oct 31, 2024
EPS Beat/Miss
-74.8%
Price Before
$46.30
Price After
$44.43
Q3 FY2024-4.09%
Report Date
Aug 1, 2024
EPS Beat/Miss
-7.0%
Price Before
$46.40
Price After
$44.50
Avg Beat Reaction+5.38%
Avg Miss Reaction-1.87%
Beat Rate4 / 8 quarters
Largest Move+13.10% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AGIO ends December
Agios Pharmaceuticals, Inc. (AGIO) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-1.69 — beating the analyst consensus of $-1.81 by +6.6%. AGIO has beaten EPS estimates for 3 consecutive quarters. The next AGIO earnings date is expected around September 1, 2026.
Each quarter, investors track AGIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AGIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AGIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AGIO earnings · 5 questionsAgios Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. AGIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AGIO historically reports after market close (AMC).
AGIO earnings datewhen is AGIO earningsAGIO next earnings datewhen does AGIO report earningsAGIO earnings calendar
▸ Source: FMP · Agios Pharmaceuticals, Inc. SEC filings · US GAAP · Agios Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026